

WEIGHT LOSS MEDICATIONS

Adipex-P* (phentermine), Lomaira (phentermine), phentermine **Benzphetamine** Contrave (naltrexone and bupropion) Diethylpropion **Phendimetrazine** Plenity* (carboxymethylcellulose-cellulose-citric acid) **Qsymia** (phentermine and topiramate extended-release) Xenical (orlistat)

Pre - PA Allowance

None

Prior-Approval Requirements

Prior authorization for *Adipex-P and *Plenity applies only to formulary exceptions due to being a non-covered medication.

Age

17 years of age or older: *Adipex-P, Contrave, diethylpropion, Lomaira, phendimetrazine capsules, phentermine, Plenity

12 years of age or older: benzphetamine, phendimetrazine tablets, Qsymia,

Xenical

Diagnosis

Patient must be using for the following:

Chronic weight management

AND ALL of the following:

- 1. Patient has **ONE** of the following:
 - a. Age 18+, must have **ONE** of the following:
 - i. Body mass index (BMI) ≥ 30 kg/m²
 - ii. Body mass index (BMI) ≥ 27 kg/m² **AND ONE** of the following:
 - 1. Patient has established cardiovascular disease (e.g., congenital heart disease, cerebrovascular disease, peripheral artery disease, coronary heart disease, acute coronary syndrome (ACS), myocardial infarction (MI), unstable angina, coronary or other arterial revascularization, or prior percutaneous coronary intervention/coronary bypass surgery)

^{*}Prior authorization for the brand formulation applies only to formulary exceptions due to being a noncovered medication.



WEIGHT LOSS MEDICATIONS

Adipex-P* (phentermine), Lomaira (phentermine), phentermine
Benzphetamine
Contrave (naltrexone and bupropion)
Diethylpropion
Phendimetrazine
Plenity* (carboxymethylcellulose-cellulose-citric acid)
Qsymia (phentermine and topiramate extended-release)
Xenical (orlistat)

- 2. Patient has at least one weight related comorbid condition (e.g., type 2 diabetes mellitus, dyslipidemia, or hypertension)
- b. Age 12-17 ONLY: Body mass index (BMI) ≥95th percentile for their age
- 2. Patient has participated in a comprehensive weight management program (e.g., Teladoc or another weight loss program)
- 3. **NO** dual therapy with another Prior Authorization (PA) medication for weight loss (see Appendix 1)

Prior - Approval Limits

Quantity

Medication	Quantity Limit
Benzphetamine	270 tablets per 90 days OR
Contrave	360 tablets per 90 days OR
Diethylpropion 25mg	270 tablets per 90 days OR
Diethylpropion 75mg	90 tablets per 90 days OR
Lomaira	270 tablets per 90 days OR
Phendimetrazine 35mg	270 tablets per 90 days OR
Phendimetrazine 105mg	90 capsules per 90 days OR
Phentermine	90 units per 90 days OR
Qsymia	90 capsules per 90 days OR
Xenical	270 capsules per 90 days OR

Medication	Quantity Limit
with approved formulary	
exception only	
Adipex-P	90 units per 90 days OR
Plenity	504 capsules per 84 days

^{*}Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication.



WEIGHT LOSS MEDICATIONS

Adipex-P* (phentermine), Lomaira (phentermine), phentermine
Benzphetamine
Contrave (naltrexone and bupropion)
Diethylpropion
Phendimetrazine
Plenity* (carboxymethylcellulose-cellulose-citric acid)
Qsymia (phentermine and topiramate extended-release)
Xenical (orlistat)

*Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication.

Duration 6 months

Prior - Approval Renewal Requirements

Prior authorization for *Adipex-P and *Plenity applies only to formulary exceptions due to being a non-covered medication.

Age

17 years of age or older: *Adipex-P, Contrave, diethylpropion, Lomaira, phendimetrazine capsules, phentermine, Plenity

12 years of age or older: benzphetamine, phendimetrazine tablets, Qsymia, Xenical

Diagnosis

Patient must be using for the following:

Chronic weight management

AND ALL of the following:

- Age 18+ ONLY: The patient has lost at least 5 percent of baseline body weight OR the patient continued to maintain their initial 5 percent weight loss
- Age 12-17 ONLY: Patient has maintained clinically significant weight loss
- 3. Patient has participated in a comprehensive weight management program (e.g., Teladoc or another weight loss program)
- 4. **NO** dual therapy with another Prior Authorization (PA) medication for weight loss (see Appendix 1)

Prior - Approval Renewal Limits Quantity

Medication	Quantity Limit
Benzphetamine	270 tablets per 90 days OR



WEIGHT LOSS MEDICATIONS

Adipex-P* (phentermine), Lomaira (phentermine), phentermine
Benzphetamine
Contrave (naltrexone and bupropion)
Diethylpropion
Phendimetrazine
Plenity* (carboxymethylcellulose-cellulose-citric acid)
Qsymia (phentermine and topiramate extended-release)
Xenical (orlistat)

^{*}Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication.

Contrave	360 tablets per 90 days OR
Diethylpropion 25mg	270 tablets per 90 days OR
Diethylpropion 75mg	90 tablets per 90 days OR
Lomaira	270 tablets per 90 days OR
Phendimetrazine 35mg	270 tablets per 90 days OR
Phendimetrazine 105mg	90 capsules per 90 days OR
Phentermine	90 units per 90 days OR
Qsymia	90 capsules per 90 days OR
Xenical	270 capsules per 90 days OR

Medication with approved formulary exception only	Quantity Limit
Adipex-P	90 units per 90 days OR
Plenity	504 capsules per 84 days

Duration 12 months



WEIGHT LOSS MEDICATIONS

Adipex-P* (phentermine), Lomaira (phentermine), phentermine
Benzphetamine
Contrave (naltrexone and bupropion)
Diethylpropion
Phendimetrazine
Plenity* (carboxymethylcellulose-cellulose-citric acid)
Qsymia (phentermine and topiramate extended-release)
Xenical (orlistat)

Appendix 1 - List of PA Weight Loss Medications

Generic Name	Brand Name
benzphetamine	N/A
carboxymethylcellulose- cellulose-citric acid	Plenity
diethylpropion	N/A
liraglutide	Saxenda
naltrexone/bupropion	Contrave
orlistat	Xenical
phendimetrazine	N/A
phentermine	Adipxex-P/Lomaira
phentermine/topiramate ER	Qsymia
semaglutide	Wegovy
setmelanotide	Imcivree
tirzepatide	Zepbound

^{*}Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication.